Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study

被引:18
作者
Gu, Xiaobin [1 ]
Gao, Xianshu [1 ]
Cui, Ming [1 ]
Xie, Mu [1 ]
Ma, Mingwei [1 ]
Qin, Shangbin [1 ]
Li, Xiaoying [1 ]
Qi, Xin [1 ]
Bai, Yun [1 ]
Wang, Dian [2 ]
机构
[1] Peking Univ, Hosp 1, Dept Radiat Oncol, 7 Xishiku St, Beijing 100034, Peoples R China
[2] Rush Univ, Med Ctr, Dept Radiat Oncol, 500 S Paulina St,Atrium Bldg,Ground Floor, Chicago, IL 60612 USA
关键词
prostate cancer; SEER; radical prostatectomy; EBRT; RADIATION-THERAPY; ADJUVANT RADIOTHERAPY; MEN;
D O I
10.2147/CMAR.S157442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study was aimed to compare survival outcomes in high-risk prostate cancer (PCa) patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP). Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify PCa patients with high-risk features who received RP alone or EBRT alone from 2004 to 2008. Propensity-score matching (PSM) was performed. Kaplan-Meier survival analysis was used to compare cancer-specific survival (CSS) and overall survival (OS). Multivariate Cox regression analysis was used to identify independent prognostic factors. Results: A total of 24,293 patients were identified, 14,460 patients receiving RP and 9833 patients receiving EBRT. Through PSM, 3828 patients were identified in each group. The mean CSS was 128.6 and 126.7 months for RP and EBRT groups, respectively (p<0.001). The subgroup analyses showed that CSS of the RP group was better than that of the EBRT group for patients aged <65 years (p<0.001), White race (p<0.001), and married status (p<0.001). However, there was no significant difference in CSS for patients aged >= 65 years, Black race, other race, and unmarried status. Similar trends were observed for OS. Multivariate analysis showed that EBRT treatment modality, T3-T4 stage, Gleason score 8-10, and prostate-specific antigen >20 ng/mL were significant risk factors for both CSS and OS. Conclusion: This study suggested that survival outcomes might be better with RP than EBRT in high-risk PCa patients aged <65 years; however, RP and EBRT provided equivalent survival outcomes in older patients, which argues for primary radiotherapy in this older cohort.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 22 条
[1]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[2]  
2-B
[3]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[4]   Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial [J].
Dearnaley, David P. ;
Jovic, Gordana ;
Syndikus, Isabel ;
Khoo, Vincent ;
Cowan, Richard A. ;
Graham, John D. ;
Aird, Edwin G. ;
Bottomley, David ;
Huddart, Robert A. ;
Jose, Chakiath C. ;
Matthews, John H. L. ;
Millar, Jeremy L. ;
Murphy, Claire ;
Russell, J. Martin ;
Scrase, Christopher D. ;
Parmar, Mahesh K. B. ;
Sydes, Matthew R. .
LANCET ONCOLOGY, 2014, 15 (04) :464-473
[5]   Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer [J].
Donovan, J. L. ;
Hamdy, F. C. ;
Lane, J. A. ;
Mason, M. ;
Metcalfe, C. ;
Walsh, E. ;
Blazeby, J. M. ;
Peters, T. J. ;
Holding, P. ;
Bonnington, S. ;
Lennon, T. ;
Bradshaw, L. ;
Cooper, D. ;
Herbert, P. ;
Howson, J. ;
Jones, A. ;
Lyons, N. ;
Salter, E. ;
Thompson, P. ;
Tidball, S. ;
Blaikie, J. ;
Gray, C. ;
Bollina, P. ;
Catto, J. ;
Doble, A. ;
Doherty, A. ;
Gillatt, D. ;
Kockelbergh, R. ;
Kynaston, H. ;
Paul, A. ;
Powell, P. ;
Prescott, S. ;
Rosario, D. J. ;
Rowe, E. ;
Davis, M. ;
Turner, E. L. ;
Martin, R. M. ;
Neal, D. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1425-1437
[6]   10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer [J].
Hamdy, F. C. ;
Donovan, J. L. ;
Lane, J. A. ;
Mason, M. ;
Metcalfe, C. ;
Holding, P. ;
Davis, M. ;
Peters, T. J. ;
Turner, E. L. ;
Martin, R. M. ;
Oxley, J. ;
Robinson, M. ;
Staffurth, J. ;
Walsh, E. ;
Bollina, P. ;
Catto, J. ;
Doble, A. ;
Doherty, A. ;
Gillatt, D. ;
Kockelbergh, R. ;
Kynaston, H. ;
Paul, A. ;
Powell, P. ;
Prescott, S. ;
Rosario, D. J. ;
Rowe, E. ;
Neal, D. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) :1415-1424
[7]   Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer [J].
Kalbasi, Anusha ;
Li, Jiaqi ;
Berman, Abigail T. ;
Swisher-McClure, Samuel ;
Smaldone, Marc ;
Uzzo, Robert G. ;
Small, Dylan S. ;
Mitra, Nandita ;
Bekelman, Justin E. .
JAMA ONCOLOGY, 2015, 1 (07) :897-906
[8]   Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin tables) based on cases from 2000 to 2005 [J].
Makarov, Danil V. ;
Trock, Bruce J. ;
Humphreys, Elizabeth B. ;
Mangold, Leslie A. ;
Walsh, Patrick C. ;
Epstein, Jonathan I. ;
Partin, Alan W. .
UROLOGY, 2007, 69 (06) :1095-1101
[9]   Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines [J].
Mohler, James L. ;
Armstrong, Andrew J. ;
Bahnson, Robert R. ;
D'Amico, Anthony Victor ;
Davis, Brian J. ;
Eastham, James A. ;
Enke, Charles A. ;
Farrington, Thomas A. ;
Higano, Celestia S. ;
Horwitz, Eric M. ;
Hurwitz, Michael ;
Kane, Christopher J. ;
Kawachi, Mark H. ;
Kuettel, Michael ;
Lee, Richard J. ;
Meeks, Joshua J. ;
Penson, David F. ;
Plimack, Elizabeth R. ;
Pow-Sang, Julio M. ;
Raben, David ;
Richey, Sylvia ;
Roach, Mack, III ;
Rosenfeld, Stan ;
Schaeffer, Edward ;
Skolarus, Ted A. ;
Small, Eric J. ;
Sonpavde, Guru ;
Srinivas, Sandy ;
Strope, Seth A. ;
Tward, Jonathan ;
Shead, Dorothy A. ;
Freedman-Cass, Deborah A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (01) :19-30
[10]   Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy [J].
Peeters, STH ;
Heemsbergen, WD ;
Koper, PCM ;
van Putten, WLJ ;
Slot, A ;
Dielwart, MFH ;
Bonfrer, JMG ;
Incrocci, L ;
Lebesque, AV .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :1990-1996